Hims & Hers Health Inc. Aktie News

LOS ANGELES, July 15, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).

LOS ANGELES , July 15, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to inves...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing...

NEW YORK , July 14, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025 lead plaintiff deadline. So what: If you purchased Hims common stock during the Class Period you may be e...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options

PHILADELPHIA , July 10, 2025 /PRNewswire/ --  Berger Montague , a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Investor Deadline:  Investors who purchased or acquired Hims & Hers securities between April 29, 2025 and June 22, 2025 (the "Class Period") may, no later than ...

LOS ANGELES , July 10, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS). IF YOU SUFFERED A LOSS ON YOUR HIMS INVESTMENTS, CLICK  HERE  BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAU...

Hims & Hers (NYSE:HIMS) announced plans to expand its digital health and weight loss services to Canada in 2026, coinciding with the first global availability of generic semaglutide. Beginning in January 2026, Canada will become the first country to offer generic versions of semaglutide, a GLP-1 receptor agonist widely used for weight management under brand names such as Wegovy and Ozempic.